EP Patent

EP2529757A1 — Paliperidone implant formulation

Assigned to Laboratorios Farmaceuticos Rovi SA · Expires 2012-12-05 · 13y expired

What this patent protects

An injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprisinga drug which is paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, a biocompatible copolymer based on lactic and glycolic acid having …

USPTO Abstract

An injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprisinga drug which is paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 8 weeks and wherein the composition has a pharmacokinetic profile in vivo suitable for the formulation to be administered each 8 weeks or even longer periods.

Drugs covered by this patent

Patent Metadata

Patent number
EP2529757A1
Jurisdiction
EP
Classification
—
Expires
2012-12-05
Drug substance claim
No
Drug product claim
No
Assignee
Laboratorios Farmaceuticos Rovi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.